<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>ECNU-China: Judging Session</title>
        <link>https://video.igem.org/videos/watch/42c3ddb7-032b-401d-bec7-a7b53ae409d7</link>
        <description>PREVAIL (Pre-Existing Viral Immunity–Enabled Universal Bacterial Tumor Vaccine) is a broad-spectrum bacterial vaccine platform that leverages the widespread pre‑existing immunity against SARS‑CoV‑2 (from prior infection or vaccination) in the human population to activate antitumor responses. The vaccine uses engineered bacteria as carriers to present SARS‑CoV‑2 epitopes within the tumor microenvironment, thereby “hijacking” established COVID‑19‑specific memory T cells to rapidly elicit potent and durable antitumor immunity. It also overcomes inter‑individual immune heterogeneity and enables universal application across diverse tumor types.</description>
        <lastBuildDate>Fri, 20 Nov 2026 22:29:56 GMT</lastBuildDate>
        <docs>https://validator.w3.org/feed/docs/rss2.html</docs>
        <generator>PeerTube - https://video.igem.org</generator>
        <image>
            <title>ECNU-China: Judging Session</title>
            <url>https://video.igem.org/client/assets/images/icons/icon-1500x1500.png</url>
            <link>https://video.igem.org/videos/watch/42c3ddb7-032b-401d-bec7-a7b53ae409d7</link>
        </image>
        <copyright>All rights reserved, unless otherwise specified in the terms specified at https://video.igem.org/about and potential licenses granted by each content's rightholder.</copyright>
        <atom:link href="https://video.igem.org/feeds/video-comments.xml?videoId=42c3ddb7-032b-401d-bec7-a7b53ae409d7" rel="self" type="application/rss+xml"/>
    </channel>
</rss>